# Invistics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/invistics

- Industry: Software
- Headquarters: Norcross, US
- Website: www.invistics.com
- Total disclosed funding: $7.5M
- Latest round: Series B (Jan 28, 2005)
- Investors on record: 4

## About

Based in the US, Invistics Corp specializes in clinical surveillance solutions that leverage advanced technology to enhance drug diversion management in healthcare settings.Invistics Corp, founded in 1999 in Norcross, US, operates as a provider of clinical surveillance solutions. Tom Knight serves as both the founder and CEO, who has a history of other entrepreneurial ventures. The company has engaged in 3 funding rounds, with the latest being a Series B round, raising USD 5.00 mn on June 7, 2023. Recent investments were made by H.I.G. BioHealth Partners, Imlay Investments, and Intersouth Partners.Invistics Corp offers a suite of clinical surveillance tools, prominently featuring Sentri7, which applies advanced technology and machine learning to address drug diversion in healthcare facilities. This solution integrates data from various IT systems, including Automated Dispensing Cabinets and Electronic Health Records, providing comprehensive insights into medication inventory and compliance with regulatory standards. The company caters to hospitals, pharmacies, and legal departments across North America, Europe, and Asia-Pacific.Invistics Corp generates revenue through subscription-based services and software licensing, where clients enter annual agreements for access to products like Sentri7. Pricing structures are designed to accommodate varying levels of usage and license requirements, ensuring flexibility for diverse organizations. The company's offerings include compliance solutions and clinical decision support systems, emphasizing their role in regulated compliance and healthcare sectors.Following its acquisition by Wolters Kluwer N.V. in June 2023, Invistics Corp plans to expand its product offerings and geographic reach. The company aims to introduce new products and enhance its existing solutions to better serve its client base. The recent funding will be strategically utilized to support these growth initiatives and to penetrate additional markets in North America and Europe by the end of 2024.

## Funding rounds

- Series B, Jan 28, 2005, $5M — Intersouth Partners, H.I.G. BioHealth Partners, Imlay Investments
- Series A, Aug 28, 2003, $2.5M — Intersouth Partners, H.I.G. BioHealth Partners, Atlanta Technology Angels, Imlay Investments

## Investors

- Intersouth Partners (https://capitalatlas.ai/funds/intersouth-partners) — Series A, Series B
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series A, Series B
- Atlanta Technology Angels (https://capitalatlas.ai/funds/atlanta-technology-angels) — Series A
- Imlay Investments (https://capitalatlas.ai/funds/imlay-investments) — Series A, Series B